Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

A new microchip invented by Scripps Research scientists can reveal how a person’s antibodies interact with viruses—using just a drop of blood. The technology offers researchers faster, clearer ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Non-Modifiable Factors and Botox Many factors that determine how long it takes Botox to work are unchangeable, such as age, metabolism, and ethnicity. That said, the injection method, dosage, and ...

HIV causes AIDS, a chronic or ongoing medical condition that can be fatal. The virus damages the immune system reducing the body’s ability to fight infection and diseases.

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.